Pharmacology of emerging novel platelet inhibitors.
A number of promising antiplatelet therapies currently in advanced clinical testing offer hope for improving cardiovascular outcomes in patients with acute coronary syndromes and those undergoing percutaneous interventions. We review the preclinical pharmacology and selected ongoing clinical trials of promising novel platelet inhibitor therapies.
Angiolillo
Dominick J
DJ
Division of Cardiology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL.
Capranzano
Piera
P
D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D000249:Adenosine Monophosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D007783:Lactones / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D000068799:Prasugrel Hydrochloride; D058919:Purinergic P2 Receptor Antagonists; D011725:Pyridines / Q000494:pharmacology; D018179:Receptors, Thrombin / Q000037:antagonists & inhibitors; D013876:Thiophenes / Q000494:pharmacology; D000077486:Ticagrelor
D007783:Lactones; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D058919:Purinergic P2 Receptor Antagonists; D011725:Pyridines; D018179:Receptors, Thrombin; D013876:Thiophenes; D000249:Adenosine Monophosphate; C117446:cangrelor; D000068799:Prasugrel Hydrochloride; D000077486:Ticagrelor; D000241:Adenosine; C530299:vorapaxar